Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bridgebio Pharma Inc (NQ: BBIO )

11.08 -0.48 (-4.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,596,604
Open 11.64
Bid (Size) 9.000 (1)
Ask (Size) 11.17 (1)
Prev. Close 11.56
Today's Range 10.89 - 11.67
52wk Range 4.980 - 53.57
Shares Outstanding 148,246,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga

Performance

YTD
-35.43%
-35.43%
1 Month
+26.48%
+26.48%
3 Month
+49.13%
+49.13%
6 Month
+24.35%
+24.35%
1 Year
-77.61%
-77.61%

More News

Read More
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
Via Benzinga
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease
Via Benzinga
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
Via Benzinga
Where BridgeBio Pharma Stands With Analysts
Via Benzinga
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'
Via Benzinga
89 Biggest Movers From Friday
Via Benzinga
BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial
Via Benzinga
BridgeBio Pharma's Return On Capital Employed Insights
Via Benzinga
6 Analysts Have This to Say About BridgeBio Pharma
Via Benzinga
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder
Via Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Via Benzinga
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Via Benzinga
What 6 Analyst Ratings Have To Say About BridgeBio Pharma
Via Benzinga
Where BridgeBio Pharma Stands With Analysts
Via Benzinga
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Sentynl Buys BridgeBio Pharma's Fosdenopterin Rights In Genetic Disorder
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.